GSK3502421

GSK3502421 is an orally available small‑molecule inhibitor of Receptor Interacting Serine/Threonine Kinase 1 (RIPK1), developed by GSK and out‑licensed to Boston Pharmaceuticals, for the treatment of potential neurological disorders.[1][3][5][9][11] RIPK1 is a key signaling kinase in the TNF‑driven inflammation and necroptosis pathway, and pharmacologic inhibition of RIPK1 is being explored to modulate inflammatory and cell-death processes implicated in neurodegenerative and other neurologic diseases.[1][11][14] As an early‑stage, pre‑phase 2 asset, GSK3502421 remains an investigational agent with no approved indications.[1][3][5][9][11]